Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Ca-19-9, A new marker for gastrointestinal malignancy

  • 20 Accesses

  • 3 Citations


Ca-19-9 and CEA were measured in serum from patients with a variety of malignancies. Ca-19-9 was elevated in 97% of 30 patients with pancreatic carcinoma and 53% of 15 patients with gastric carcinomas. The main advantage of Ca-19-9 over CEA as a marker for gastrointestinal malignancy is the low number of false positive elevations in patients with benign gastrointestinal disease. It is concluded that Ca-19-9 is the best presently available biochemical marker for cancer of the pancreas.

This is a preview of subscription content, log in to check access.


  1. Del Villano, B. C., Brennan, S., Brock, P.ef al. 1983. Radioimmunometric assay for a monoclonal-defined tumor marker Ca-19-9. Clin. Chem. 29, 549–552.

  2. Koprowski, H., Herlyn, M., Steplewski, Z. and Sears, H. F. 1981. Specific antigen in serum of patients with colon cancer. Science 212, 53–55.

  3. NIH Consensus Statement, 1981. Carcinoembryonic antigen: its role as a marker in the management of cancer. Br. Med. J. 282, 373–375.

Download references

Author information

Correspondence to M. J. Duffy or F. O’Sullivan or D. O’Donoghue or N. H. Afdhal or D. Kelleher.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Duffy, M.J., O’Sullivan, F., O’Donoghue, D. et al. Ca-19-9, A new marker for gastrointestinal malignancy. I.J.M.S. 154, 385 (1985). https://doi.org/10.1007/BF02937186

Download citation


  • Pancreatitis
  • Esophageal Cancer
  • Gastric Carcinoma
  • Biochemical Marker
  • Pancreatic Carcinoma